Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $1.8 million.

  • Amylyx Pharmaceuticals' Interest & Investment Income fell 4122.01% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 4750.38%. This contributed to the annual value of $13.8 million for FY2024, which is 1452.18% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Interest & Investment Income is $1.8 million, which was down 4122.01% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Interest & Investment Income peaked at $4.4 million during Q4 2023, and registered a low of $1000.0 during Q2 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.2 million (2025), whereas its average is $2.1 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first surged by 4010000.0% in 2022, then tumbled by 5183.09% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Interest & Investment Income (Quarter) stood at $30000.0 in 2021, then skyrocketed by 10423.33% to $3.2 million in 2022, then skyrocketed by 38.45% to $4.4 million in 2023, then plummeted by 47.01% to $2.3 million in 2024, then dropped by 21.37% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.0 million for Q2 2025, and $2.2 million during Q1 2025.